The PDGFB gene is found at 22q12.3-q13.1, and the COL1A1 gene is located at 17q21.3-q22.1. If the COL1A1 gene of 17q21-22 is fused with the PDGFB gene of 22q13.1, then it forms a new COL1A1-PDGFB fusion gene, one that has been found in dermatofibrosarcoma protuberans (DFSP) and lasts for many years. The expression of PDGFB loses the regulation of upstream inhibitory factors and leads to the mass production of COL1A1-PDGFB chimeric mRNA under the initiation of COL1A1 sequence, a crucial factor in the development of DFSP. In our study, we retrospectively analyzed 2 cases: case 1 is a 25-year-old student with three surgical resections in his right lumbar region. Initially, his diagnosis (from another hospital in 2009) was vascular lymphangioma. When the disease recurred after 6 years, he went to our hospital and the diagnosis was giant cell fibroblastoma (GCF). Molecular pathology (using the fluorescence in situ hybridization, FISH) showed the COL1A1-PDGFB gene fusion, presented as the fusion of 3 or more red and green signals. In 2017, the patient had another recurrence of the disease, and he underwent a third surgical resection. The other case is a 51-year-old woman who had presented with pain in her left lumbosacral, accompanied by left buttock and left thigh numbness for 3 months. The diagnosis was DFSP, which also showed COL1A1-PDGFB gene fusion. Here we review the clinicopathologic features and differential diagnosis of this rare tumor, so that it can be better recognized.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962820 | PMC |
Front Oncol
November 2024
Department of Plastic and Aesthetic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Objective: Dermatofibrosarcoma protuberans (DFSP) is a moderately malignant soft tissue sarcoma with localized infiltrative growth. The extensive surgical scope and high recurrence rate of DFSP brings dysfunctional, aesthetic, psychological and economic problems to patients. The aim of this study is to explore the global publication characteristics, research hotspots and future trends of DFSP over the past 32 years via an intuitive visualized way.
View Article and Find Full Text PDFJ Mol Diagn
January 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address:
An amplicon-based targeted next-generation sequencing (NGS) assay for the detection of gene fusions in sarcomas was developed, validated, and implemented. This assay can detect fusions in targeted regions of 138 genes and BCOR internal tandem duplications. This study reviews our experience with testing on the first 652 patients analyzed.
View Article and Find Full Text PDFCancers (Basel)
September 2024
Scientific Circle of the Department of Gynecology and Obstetrics, University of Warmia and Mazury in Olsztyn, 10-045 Olsztyn, Poland.
Exp Dermatol
August 2024
Department of Dermatology, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous sarcoma characterized by the COL1A1-PDGFB fusion gene. This study utilized single-cell RNA sequencing to dissect the cellular and molecular landscape of primary DFSP. Distinct DFSP cell clusters, exhibiting fibroblast-like traits, revealed variations in pathways associated with proliferation, inflammation and metabolism.
View Article and Find Full Text PDFHum Cell
May 2024
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Dermatofibrosarcoma protuberans (DFSP) is the most prevalent dermal sarcoma, characterized by the presence of the fusion of the collagen type I alpha 1 (COL1A1) gene with the platelet-derived growth factor beta chain (PDGFB) gene. Although PDGF receptor inhibitor imatinib mesylate was approved for the treating patients with unresectable or metastatic DFSP, disease progression was shown in 9.2% of the patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!